Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study

Compugen Ltd. announced that the first patient has been dosed in the triple combination proof-of-concept study evaluating COM701, Compugen’s potential first-in-class anti-PVRIG antibody, in combination with COM902, Compugen’s potential best-in-class anti-TIGIT antibody, and pembrolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC).